Fiocruz seeks volunteers to test Pfizer’s Covid-19 drug

The Instituto de Infectologia Evandro Chagas (INI/Fiocruz) is looking for new volunteers to test the drug for oral use paxlovid Against the Covid-19 . The institute is responsible for the tests, in Rio de Janeiro, of the drug developed by the pharmaceutical company pfizer .

To participate, you must be 18 years of age or older, have symptoms and a positive result for Covid-19 for less than five days and have been vaccinated against the disease for the last time more than 12 months ago. This last condition makes the study aimed at people who have not been vaccinated or who have an incomplete therapeutic regimen (only the first or second dose). According to Fiocruz this is the clinical trial protocol to be able to test the effectiveness of the drug.

In addition to these criteria, the infectology institute informs that the volunteers will undergo a medical evaluation with more detailed criteria. To apply, you must contact us by phone (21) 99784-9876.

The drug has previously been tested in high-risk patients, which has allowed its emergency use to be cleared by regulatory agencies such as FDA (USA) and the National Health Surveillance Agency (Anvisa). The results showed that the drug, which combines the antivirals nirmatrelvir and ritonavir, reduced hospitalization for the disease and deaths by 89% in those patients.

The test that is now being conducted in several places around the world, with the participation of Fiocruz in Rio de Janeiro, seeks to find out if the drug is safe and effective to treat mild cases of the disease in low-risk patients. The study is in phases 2 and 3, in which the efficacy and safety of the drug are evaluated, and should involve 1,980 participants. The first volunteer was recruited and included in the study on June 9.